Endo to buy Par Pharmaceuticals for $8.05B

Stock Market Blue Concept Illustration. Stock Exchange Building in Lower Manhattan, New York City and Stock Graphs and Ticker Composition. Business Financial Backdrop

"This will position us as a top-five generics player in the U.S.," Endo International CEO Rajiv De Silva says.
Source: CNBC Business